Joshua Mercure

Joshua Mercure

Auto-generated profile, based on publicly available information

Joshua Mercure

Department of Pharmacy, Massachusetts General Hospital , Boston, Massachusetts 02114

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 September 2025 in Open Forum Infectious Diseases
Verified
Journal Article
Open access
JMJoshua Mercure
Joshua Mercure
KBKayla Bey
Kayla Bey
EGEric Gillett
Eric Gillett
JPJeffrey Pearson
Jeffrey Pearson
SMSuzanne M McCluskey
Suzanne M McCluskey
ARAlex E Rock
Alex E Rock
Human immunodeficiency virus (HIV) viral suppression was evaluated after receipt of crushed or dissolved bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) administered via enteral tube during hospitalization. Eighty-nine percent of patients (17/19) were virally suppressed (<200 copies/mL) within 1 year of receiving B/F/TAF via tube, suggesting that administration via tube is a reasonable alternative to changing antiretroviral regimens.